R. Klecker

发表

Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.

P. Sugarbaker, R. Dedrick, C. Myers, 1981, Cancer research.

Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.

R. Glazer, J. Trepel, T. Smithgall, 1993, Biochemistry.

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Y. Ostchega, R. Ozols, J. Parrillo, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

E. Gelmann, H. Mitsuya, S. Broder, 1986, The Lancet.

Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug–drug interactions

P. LoRusso, R. Parchment, S. Ivy, 2005, Cancer Chemotherapy and Pharmacology.

Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography.

C. Takimoto, J. Grem, C. Allegra, 1994, Journal of chromatography. B, Biomedical applications.

Dextran sulfate is poorly absorbed after oral administration.

C. Flexner, C. Hendrix, P. Lietman, 1989, Annals of internal medicine.

Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors.

J. Collins, R. Cysyk, R. Klecker, 2006, Bioorganic & medicinal chemistry.

Distribution of 1-(2-Deoxy-2-fluoro-β-d-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts

Paul Kinahan, C. Mathis, M. Egorin, 2004, Clinical Cancer Research.

Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.

Paul Kinahan, C. Mathis, M. Egorin, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Glucuronidation of 3′-Azido-3′-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid

C. Jamis-Dow, J. Collins, R. Klecker, 1998, Antimicrobial Agents and Chemotherapy.

Reversal of resistance to adriamycin by 8-chloro-cyclic AMP in adriamycin-resistant HL-60 leukemia cells is associated with reduction of type I cyclic AMP-dependent protein kinase and cyclic AMP response element-binding protein DNA-binding activities.

R. Glazer, Y. Cho‐Chung, C. Rohlff, 1993, Molecular pharmacology.

Selenium-induced cytotoxicity of human leukemia cells: interaction with reduced glutathione.

G. Batist, C. Myers, A. Katki, 1986, Cancer research.

Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.

W. Wilson, S. Steinberg, R. Wittes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection

R. Redfield, A. Fauci, H. Lane, 1986, Journal of clinical pharmacology.

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex.

C. Simone, L. Gianni, R. Greene, 1982, Biochemistry.

Reversal of adriamycin resistance by verapamil in human ovarian cancer.

R. Ozols, T. Hamilton, R. Young, 1984, Science.

Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.

P. Watkins, C. Jamis-Dow, J. Collins, 1997, American journal of clinical oncology.

Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines.

M. Winker, T. Tsuruo, R. Ozols, 1986, Biochemical pharmacology.

Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer

E. Reed, C. Jamis-Dow, J. Collins, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders

S. Broder, R. Yarchoan, C. Myers, 1988, Journal of clinical pharmacology.

PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)

H. Mitsuya, S. Broder, B. Safai, 1988, The Lancet.

Incorporation of iododeoxyuridine into DNA of granulocytes in patients.

K. Bélanger, T. Kinsella, J. Collins, 1986, Cancer research.

Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences

C. Jamis-Dow, J. Collins, A. Katki, 2004, Cancer Chemotherapy and Pharmacology.

Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid.

F. Balis, D. Poplack, J. Collins, 1988, The Journal of pharmacology and experimental therapeutics.

Radiosynthesis of [11C]paclitaxel

R. Wahl, M. Pomper, R. Dannals, 2002 .

Clinical pharmacology of 5‐iodo‐2′‐deoxyuridine and 5‐iodouracil and endogenous pyrimidine modulation

R. Fine, T. Kinsella, J. Strong, 1985, Clinical pharmacology and therapeutics.

Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

S. Broder, R. Yarchoan, J. Jenkins, 1987, Clinical pharmacology and therapeutics.

Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU.

A. Shields, T. Mangner, R. Klecker, 2003, Nuclear medicine and biology.

Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells.

J. Collins, A. Katki, R. Klecker, 1994, Molecular pharmacology.

Synthesis of 2′-[F-18]fluoro-2′-DEOXY-β-D-arabinofuranosyl nucleosides

A. Shields, T. Mangner, R. Klecker, 2001 .

Technique for detection of DNA nucleobases by reversed-phase high-performance liquid chromatography optimized for quantitative determination of thymidine substitution by iododeoxyuridine.

K. Bélanger, R. Klecker, J. Collins, 1987, Journal of chromatography.

Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.

R. Donehower, C. Erlichman, B. Chabner, 1982, Journal of the National Cancer Institute.

Iododeoxyuridine (IdUrd) incorporation into DNA of human hematopoietic cells, normal liver and hepatic metastases in man: as a radiosensitizer and as a marker for cell kinetic studies.

K. Bélanger, A. Chang, J. Cupp, 1989, International journal of radiation oncology, biology, physics.

Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver

K. Bélanger, A. Chang, T. Kinsella, 1988, Clinical pharmacology and therapeutics.

Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study.

K. Bélanger, T. Kinsella, J. Collins, 1988, Cancer research.

Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.

S. Steinberg, T. Kinsella, J. Collins, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.

L. Gianni, T. Kinsella, E. Glatstein, 1984, Cancer research.

Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion

G. Batist, J. Grygiel, R. Fine, 2004, Investigational New Drugs.

Quantification of tiazofurin in plasma by high-performance liquid chromatography.

R. Klecker, J. Collins, 1984, Journal of chromatography.

EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO

E. Gelmann, R. Redfield, L. Resnick, 1985, The Lancet.

Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs.

O. Muzik, A. Shields, T. Mangner, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues.

J. Collins, A. Katki, R. Klecker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of Highly Bound Drugs: Interspecies, Intersubject, and Related Comparisons

J. Collins, R. Klecker, 2002, Journal of clinical pharmacology.

Rifampin and rifabutin and their metabolism by human liver esterases.

C. Jamis-Dow, J. Collins, A. Katki, 1997, Xenobiotica; the fate of foreign compounds in biological systems.

Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole

C. Jamis-Dow, J. Collins, R. Klecker, 1997, Antimicrobial agents and chemotherapy.

Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease

S. Larson, J. Grafman, M. Dalakas, 1988, Annals of neurology.

Prolonged Treatment Schedules with Intraperitoneal 5‐Fluorouracil Diminish the Local‐Regional Nature of Drug Distribution

P. Sugarbaker, J. Speyer, R. Klecker, 1986, American journal of clinical oncology.

Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.

M. Egorin, K. Erkmen, C. Jamis-Dow, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography

J. Collins, R. Klecker, 1985 .

NEUROLOGICAL INVOLVEMENT IN AIDS: TREATMENT

S. Larson, J. Grafman, M. Dalakas, 2004 .

Metabolism by N‐Acetyltransferase 1 In Vitro and in Healthy Volunteers: A Prototype for Targeted Inhibition

J. Collins, A. Katki, L. Cantilena, 2004, Journal of clinical pharmacology.

VISA: a computer code for predicting the probability of reactor pressure-vessel failure. [PWR]

J. Strosnider, F. A. Simonen, D. Engel, 1983 .

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas

J. Doroshow, A. Chen, S. Kummar, 2013, Cancer Chemotherapy and Pharmacology.